You are here

FDA Approves Tdap Vaccine for Adults Aged 19-64 Years

PHILADELPHIA, PA--(MARKET WIRE)--Dec 8, 2008 -- GlaxoSmithKline (NYSE:GSK - News) announced today that the U.S. Food and Drug Administration (FDA) has approved BOOSTRIX® [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for use in adults 19-64 years of age. BOOSTRIX offers protection against tetanus, diphtheria and pertussis (whooping cough) to individuals 10-64 years of age -- the broadest age range for any Tdap vaccine. BOOSTRIX was previously approved as a booster vaccine for preteens and teens.

"Whooping cough is a highly contagious respiratory disease that can be prevented through vaccination, yet, according to the Centers for Disease Control and Prevention (CDC), most adolescents and adults have not received the recommended booster shot," said Andrew C. Eisenberg MD, MHA, FAAFP, Associate Professor, Department of Public Health and Policy, Texas A&M School of Rural Public Health. "BOOSTRIX can be given in place of one tetanus diphtheria (Td) booster for adolescents and adults, in accordance with the CDC recommendation for whooping cough protection."

The approval of BOOSTRIX in adults was based on two clinical trials in which nearly 3,000 U.S. subjects 19-64 years of age were vaccinated with BOOSTRIX. The data demonstrate the overall safety and immunogenicity of BOOSTRIX in providing booster protection against tetanus, diphtheria and whooping cough in adults.

The CDC recommends a single Tdap vaccination for adults aged 19-64 years, in place of a Td booster if the last dose of the Td vaccine was received 10 or more years prior in individuals who have not already received a Tdap vaccine. This includes healthcare personnel who have direct patient contact, as well as adults younger than 65 years of age who have or anticipate having contact with infants younger than 12 months (e.g., parents, grandparents, childcare providers).

"This approval extends the whooping cough protection afforded by BOOSTRIX in adolescents to adults 19-64, expanding options for adult Tdap vaccination," said Wayde M. Weston, Ph.D., Director, U.S. Clinical Research and Development/Medical Affairs, GlaxoSmithKline.

The approval of BOOSTRIX in adults expands the GSK Vaccines portfolio, making it the only company in the country to offer a full line of vaccines to protect adults from pertussis, hepatitis A & B and flu.

About Pertussis (Whooping Cough)
Whooping cough, also known as pertussis, is a serious and highly contagious respiratory disease characterized by severe coughing fits. Whooping cough may lead to complications such as pneumonia or rib fracture in adolescents and adults. The illness may last for more than 100 days and can lead to lost time at work or school. Babies who have not received all of their shots for whooping cough are at risk of catching the illness. Preteens, teens and adults are often the source of infection for infants.

Whooping cough starts off like the common cold, and may include symptoms such as a runny nose, sneezing, mild fever and severe coughing fits. While more than 3,500 cases of whooping cough were reported in U.S. adults ages 20 years and older in 2007, many more cases may go unreported. In fact, it is estimated that over 600,000 cases occur in adults annually. According to the CDC's 2007 National Immunization Survey, an estimated 98 percent of adults aged 18-64 years reported that they have not received the whooping cough booster shot.

BOOSTRIX is approved as a booster vaccination for the prevention of tetanus, diphtheria and pertussis in individuals 10-64 years of age. Since 2005, more than 7.5 million doses of BOOSTRIX have been distributed in the US to protect adolescents from whooping cough.

Source: GlaxoSmithKline

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs